Illumina 'Wasting Court Time' With Deal Overtures, FTC Says
Federal Trade Commission staffers contesting biotech giant Illumina's planned $8 billion purchase of cancer detection company Grail assailed the companies Tuesday for seeking a settlement conference in the in-agency challenge process,...To view the full article, register now.
Already a subscriber? Click here to view full article